EUCTR2015-003324-32-BE进行中（未招募）1 期
A Phase 4 study to evaluate the safety and immunogenicity of trivalent oral polio vaccine in adults previously vaccinated with oral polio vaccine
niversity of Antwerp0 个研究点目标入组 128 人开始时间: 2015年8月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy male or female, between 18 and 50 years old, extremes included
- •2. Received at least 4 doses of OPV in the past (more than 12 months before the start of the study)
- •3. In good physical and mental health as determined on the basis of medical history and general physical examination performed at Day 0
- •4. Female subjects of childbearing potential must agree to the use of an effective method of birth control throughout the study and up to 3 months after last vaccine dose
- •5. Willing to adhere to the prohibitions and restrictions specified in this protocol
- •6. Informed Consent Form (ICF) signed voluntarily by the subject before any study-related procedure is performed, indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 128
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements
- •2. Having Crohn’s disease or ulcerative colitis or having had major surgery of the gastrointestinal tract involving significant loss or resection of the bowel
- •3. A known allergy, hypersensitivity, or intolerance to the study vaccine, or to any of its components or to any antibiotics
- •4. Any confirmed or suspected immunosuppressive or immunodeficiency condition (including human immunodeficiency virus [HIV] infection)
- •5. Will have household or professional contact with known immunosuppressed people or people without full polio vaccination (i.e. complete priming) within 28 days after vaccination
- •6. Neonatal nurses or others having professional contact with children under 6 months old within 28 days after vaccination
- •7. Chronic administration (i.e., longer than 14 days) of immunosuppressant drugs or other immune-modifying drugs within 6 months prior to the first vaccine dose or planned use during the study. For instance, for corticosteroids, this means prednisone, or equivalent, = 0.5 mg/kg/day (inhaled and topical steroids are allowed whereas intra-articular and epidural injection/administration of steroids are not allowed)
- •8. Presence of contraindications to administration of the study vaccine on Day 0: acute severe febrile illness deemed by the Investigator to be a contraindication for vaccination or persistent diarrhea or vomiting
- •9. Indications of drug abuse or excessive use of alcohol at Day 0
- •10. Being pregnant or breastfeeding. Women of childbearing potential will undergo a urine pregnancy test at Day 0. Subjects with a positive pregnancy test will be excluded
- •11. Participation in another clinical study within 28 days prior to entry in this study or receipt of any investigational product (drug or vaccine) other than the study vaccine within 28 days prior to the first administration of study vaccine, or planned use during the study period
- •12. Planned administration or administration of any vaccine other than the study vaccine within 28 days of the first dose of study vaccine and up to 28 days after administration of each study vaccine dose
- •13. Administration of polio vaccine within 12 months before the start of the study
- •14. Having had a transfusion of any blood product or application of immunoglobulins within the 4 weeks prior to the first administration of study vaccine or during the study
- •15. Subject is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, or is a family member of an employee or the Investigator.
研究者
相似试验
进行中（未招募）
1 期
A clincal study to evaluate the safety of a polio vaccine type 2 given orally in healthy children aged 1 to 5 years previously treated with inactivated polio vaccine in Lithuaniaevaluation of safety of SABIN mOPV2 in healthy IPV-vaccinated children of 1 – 5 years of age (Polio disease)MedDRA version: 18.0Level: LLTClassification code 10036016Term: Poliomyelitis NOSSystem Organ Class: 100000004862EUCTR2015-003544-39-LTFIDEC - Fighting Infectious Diseases in Emerging Countries
进行中（未招募）
1 期
A vaccine study in healthy adults to evaluate the safety and immune response of a licensed oral polio vaccine containing the polio vaccine 2 straiPolio diseaseMedDRA version: 18.0Level: HLTClassification code 10036017Term: Poliomyelitis viral infectionsSystem Organ Class: 100000004862EUCTR2015-003325-33-BEniversity of Antwerp100
尚未招募
4 期
Study to evaluate the effects of the COVID-19 (inactivated) vaccine of the Instituto Butantan in immucompromised personsChronic kidney diseaseRespiratory diseasesCOVID-19Immunocompromised hostsTransplant recipientsLiver cirrhosisNeoplasmsPrimary immunodeficiency diseasesC01.918RBR-9ksh5f4Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
进行中（未招募）
1 期
A phase I study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in healthy volunteers.SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2021-001411-82-ESABORATORIOS HIPRA, S.A.30
进行中（未招募）
1 期
Investigating a vaccine against plague in Uganda (PlaVac Uganda)Prevention of plague caused by the intracellular bacterium Yersinia pestisInfections and InfestationsISRCTN79243381niversity of Oxford36